{"filing":{"accession_number":"0001104659-26-110241","cik":"0002094256","ticker":"CLYD","company_name":"BEACON TOPCO, INC.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-22","primary_document":"tm2625953d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2094256/000110465926110241/tm2625953d2_8k.htm"},"events":[{"id":34795,"run_id":32039,"accession_number":"0001104659-26-110241","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Beacon Topco, Inc. disclosed a Second Amendment to the Agreement and Plan of Merger dated September 22, 2026, which amends the closing timeline and End Date to October 31, 2026. This amendment modifies key closing conditions for the ongoing merger transaction between Topco, Beacon, Merger Sub, and Clywedog Therapeutics.","company_name":"BEACON TOPCO, INC.","ticker":"CLYD","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38639,"accession_number":"0001104659-26-110241","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a Second Amendment to the Agreement and Plan of Merger dated September 22, 2026, which amends the closing timeline and End Date to October 31, 2026. This is a material amendment to an ongoing merger transaction between Topco, Beacon, Merger Sub, and Clywedog Therapeutics. The amendment modifies key closing conditions for the combination, making it a material definitive agreement amendment under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:19:44.632431+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34796,"run_id":32039,"accession_number":"0001104659-26-110241","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The company announced positive Phase 1b clinical trial results for balomenib, demonstrating sustained glycemic improvements three months post-treatment, with plans to initiate a Phase 2a study in Q4 2026. This represents a material clinical development milestone for the clinical-stage biopharmaceutical company's pipeline.","company_name":"BEACON TOPCO, INC.","ticker":"CLYD","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38640,"accession_number":"0001104659-26-110241","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses final results from a Phase 1b clinical trial of balomenib showing positive glycemic improvements sustained three months post-treatment, with plans to initiate a Phase 2a study in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress in pipeline development. While not fitting a specific named event type, this is clearly an operational/strategic disclosure of a material clinical development milestone that would affect investor assessment of the company's drug candidate prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:19:44.632431+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38639,"accession_number":"0001104659-26-110241","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a Second Amendment to the Agreement and Plan of Merger dated September 22, 2026, which amends the closing timeline and End Date to October 31, 2026. This is a material amendment to an ongoing merger transaction between Topco, Beacon, Merger Sub, and Clywedog Therapeutics. The amendment modifies key closing conditions for the combination, making it a material definitive agreement amendment under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:19:44.632431+00:00","company_name":"BEACON TOPCO, INC.","ticker":"CLYD","filing_date":"2026-09-24"},{"id":38640,"accession_number":"0001104659-26-110241","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses final results from a Phase 1b clinical trial of balomenib showing positive glycemic improvements sustained three months post-treatment, with plans to initiate a Phase 2a study in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company, representing significant progress in pipeline development. While not fitting a specific named event type, this is clearly an operational/strategic disclosure of a material clinical development milestone that would affect investor assessment of the company's drug candidate prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:19:44.632431+00:00","company_name":"BEACON TOPCO, INC.","ticker":"CLYD","filing_date":"2026-09-24"}]}